Logo image of NVRO

NEVRO CORP (NVRO) Stock Price, Quote, News and Overview

NYSE:NVRO - New York Stock Exchange, Inc. - US64157F1030 - Common Stock - Currency: USD

5.73  +0.02 (+0.35%)

After market: 5.73 0 (0%)

NVRO Quote, Performance and Key Statistics

NEVRO CORP

NYSE:NVRO (2/20/2025, 8:04:00 PM)

After market: 5.73 0 (0%)

5.73

+0.02 (+0.35%)

Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
Statistics
52 Week High16.12
52 Week Low3.17
Market Cap216.94M
Shares37.86M
Float36.44M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)03-04 2025-03-04/amc
IPO11-06 2014-11-06


NVRO short term performance overview.The bars show the price performance of NVRO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 10 15 20 25

NVRO long term performance overview.The bars show the price performance of NVRO in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of NVRO is 5.73 USD. In the past month the price increased by 16.94%. In the past year, price decreased by -62.55%.

NEVRO CORP / NVRO Daily stock chart

NVRO Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABT ABBOTT LABORATORIES 28.52 230.98B
ISRG INTUITIVE SURGICAL INC 82.75 216.34B
BSX BOSTON SCIENTIFIC CORP 41.98 155.28B
SYK STRYKER CORP 31.7 147.31B
MDT MEDTRONIC PLC 16.47 112.76B
BDX BECTON DICKINSON AND CO 16.39 65.45B
EW EDWARDS LIFESCIENCES CORP 28.52 44.06B
GEHC GE HEALTHCARE TECHNOLOGY 20.51 42.07B
IDXX IDEXX LABORATORIES INC 40.25 37.08B
DXCM DEXCOM INC 54.15 34.90B
RMD RESMED INC 26.33 34.19B
PHG KONINKLIJKE PHILIPS NVR- NY 17.14 23.53B

About NVRO

Company Profile

NVRO logo image Nevro Corp. engages in the development of medical devices. The company is headquartered in Redwood City, California and currently employs 1,215 full-time employees. The company went IPO on 2014-11-06. The firm is focused on delivering solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. Its comprehensive HFX spinal cord stimulation 3 (SCS) platform includes the Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy. The company has developed and commercialized its HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain, with the Senza HFX iQ platform. Its HFX solution delivers a range of waveforms, including its paresthesia-free 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain. Its products include Senza II SCS System, Senza Omnia SCS System, Senza Omnia upgrade, Omnia Powered by HFX Connect, Senza HFX iQ System, and Surpass Surgical Lead.

Company Info

NEVRO CORP

1800 Bridge Parkway

Redwood City CALIFORNIA 94065 US

CEO: D. Keith Grossman

Employees: 1215

Company Website: https://www.nevro.com

Investor Relations: https://nevro.com/English/us/investors/

Phone: 16502510005

NEVRO CORP / NVRO FAQ

What is the stock price of NEVRO CORP today?

The current stock price of NVRO is 5.73 USD. The price increased by 0.35% in the last trading session.


What is the ticker symbol for NEVRO CORP stock?

The exchange symbol of NEVRO CORP is NVRO and it is listed on the New York Stock Exchange, Inc. exchange.


On which exchange is NVRO stock listed?

NVRO stock is listed on the New York Stock Exchange, Inc. exchange.


What is the price forecast or stock price prediction for NEVRO CORP stock?

22 analysts have analysed NVRO and the average price target is 7.86 USD. This implies a price increase of 37.21% is expected in the next year compared to the current price of 5.73. Check the NEVRO CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is NEVRO CORP worth?

NEVRO CORP (NVRO) has a market capitalization of 216.94M USD. This makes NVRO a Micro Cap stock.


How many employees does NEVRO CORP have?

NEVRO CORP (NVRO) currently has 1215 employees.


What are the support and resistance levels for NEVRO CORP (NVRO) stock?

NEVRO CORP (NVRO) has a support level at 5.72 and a resistance level at 5.74. Check the full technical report for a detailed analysis of NVRO support and resistance levels.


Is NEVRO CORP (NVRO) expected to grow?

The Revenue of NEVRO CORP (NVRO) is expected to decline by -4.09% in the next year. Check the estimates tab for more information on the NVRO EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy NEVRO CORP (NVRO) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does NEVRO CORP (NVRO) stock pay dividends?

NVRO does not pay a dividend.


When does NEVRO CORP (NVRO) report earnings?

NEVRO CORP (NVRO) will report earnings on 2025-03-04, after the market close.


What is the Price/Earnings (PE) ratio of NEVRO CORP (NVRO)?

NEVRO CORP (NVRO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.77).


What is the Short Interest ratio of NEVRO CORP (NVRO) stock?

The outstanding short interest for NEVRO CORP (NVRO) is 8.03% of its float. Check the ownership tab for more information on the NVRO short interest.


NVRO Technical Analysis

ChartMill assigns a technical rating of 5 / 10 to NVRO. When comparing the yearly performance of all stocks, NVRO is a bad performer in the overall market: 84.88% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

NVRO Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to NVRO. NVRO has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NVRO Financial Highlights

Over the last trailing twelve months NVRO reported a non-GAAP Earnings per Share(EPS) of -1.77. The EPS increased by 38.11% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -11.64%
ROE -25.33%
Debt/Equity 0.81
Chartmill High Growth Momentum
EPS Q2Q%36.92%
Sales Q2Q%-6.69%
EPS 1Y (TTM)38.11%
Revenue 1Y (TTM)-0.86%

NVRO Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 50% to NVRO. The Buy consensus is the average rating of analysts ratings from 22 analysts.

For the next year, analysts expect an EPS growth of 3.89% and a revenue growth -4.09% for NVRO


Ownership
Inst Owners96.58%
Ins Owners2.07%
Short Float %8.03%
Short Ratio3.28
Analysts
Analysts50
Price Target7.86 (37.17%)
EPS Next Y3.89%
Revenue Next Year-4.09%